Curr Neuropharmacol 2011, 9:40916. 7. Kremenchutzky M, Morrow S, Rush C: The security andCurr Neuropharmacol

Curr Neuropharmacol 2011, 9:40916. 7. Kremenchutzky M, Morrow S, Rush C: The security and
Curr Neuropharmacol 2011, 9:40916. 7. Kremenchutzky M, Morrow S, Rush C: The safety and efficacy of IFN-beta items for the treatment of various PLK4 Purity & Documentation sclerosis. Specialist Opin Drug Saf 2007, six:27988. eight. SGK1 Storage & Stability Adriaansen J, Kuhlman RR, van Holten J, Kaynor C, Vervoordeldonk MJ, Tak PP: Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum Gene Ther 2006, 17:98596. 9. van Holten J, Plater-Zyberk C, Tak PP: Interferon- for remedy of rheumatoid arthritis Arthritis Res 2002, four:34652. ten. van Holten J, Smeets TJ, Blankert P, Tak PP: Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with sufferers with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005, 64:1780782. 11. van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musikic P, Tak PP: A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a inside the therapy of patients with active rheumatoid arthritis. Ann Rheum Dis 2005, 64:649. 12. Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, Tak PP: The effects of interferon- remedy of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:27074. 13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism. Association 1987 Revisedcriteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:31524. 14. Kellgren JH, Lawrence JS: Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957, 16:49402. 15. Seeuws S1, Jacques P, Van Praet J, Drennan M, Coudenys J, Decruy T, Deschepper E, Lepescheux L, Pujuguet P, Oste L, Vandeghinste N, Brys R, Verbruggen G, Elewaut D: A multiparameter method to monitor illness activity in collagen-induced arthritis. Arthritis Res Ther 2010, 12:160. 16. Al-Dujaili SA, Lau E, Al-Dujaili H, Tsang K, Guenther A, You L: Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem 2011, 112:2412423. 17. van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, Tak PP: Therapy with recombinant interferon-beta reduces inflammation and slows cartilage destruction inside the collageninduced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004, 6:23949. 18. Hutamekalin P, Saito T, Yamaki K, Mizutani N, Brand DD, Waritani T, Terato K, Yoshino S: Collagen antibody-induced arthritis in mice: development of a brand new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. J I Procedures 2009, 343:495. 19. Khachigian LM: Collagen antibody-induced arthritis. Nat Protoc 2006, 1:2512516. 20. Dimitrova P, Ivanovska N, Belenska L, Milanova V, Schwaeble W, Stover C: Abrogated RANKL expression in properdin-deficient mice is connected with greater outcome from collagen-antibody-induced arthritis. Arthritis Res Ther 2012, 14:R173.Zhao et al. Journal of Translational Medicine 2014, 12:330 translational-medicine.com/content/12/1/Page 12 of21. Nandakumar KS, Holmdahl R: Antibody-induced arthritis: illness mechanisms and genes involved in the effector phase of arthritis. Arthritis Res Ther 2006, 8:223. 22. Croxford AM, Whittingham S.